Patients must have measurable or evaluable diseaseXx_NEWLINE_xXParticipants must have measurable or evaluable diseaseXx_NEWLINE_xXRadiologically measurable or clinically evaluable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXPart A: Patients must have either measurable or evaluable diseaseXx_NEWLINE_xXParts A & C: patients must have either measurable or evaluable diseaseXx_NEWLINE_xXParts B, D & E: patients must have measurable disease for Parts B1-B6, D1-D5, E3 and E4; melanoma patients in Part B7 must have either measurable or evaluable disease; neuroblastoma patients in Parts B8 and D6 must be evaluable for MIBG response without evidence of RECIST measurable lesionsXx_NEWLINE_xXDisease status:* Part A: Patients must have either measurable or evaluable disease* Parts B and C: Patients must have measurable disease on imagingXx_NEWLINE_xXCA-125 only disease without RECIST 1.1 measurable or otherwise evaluable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xXPatients must have measurable or evaluable diseaseXx_NEWLINE_xXPatients must have either measurable or evaluable diseaseXx_NEWLINE_xX